- Patients must have completed any prior immunotherapy (e.g., rituximab or programmed cell death protein 1 [PD-1] inhibition) or antibody drug conjugate therapy (e.g. brentuximab vedotin) at least 4 weeks prior to the first dose of ibrutinib in the absence of clear disease progression.